Arena's APD418 Receives FDA's Fast Track Designation to Treat Patients with Decompensated Heart Failure
Shots:
- The US FDA has granted FT designation to APD418- currently in development for the treatment of DHF
- The FDA’s Fast Track designation facilitate the development and expedite the review of therapy to treat serious conditions and fill an unmet medical need
- APD418 is a first-in-class β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope- designed to improve cardiac contractility with minimal effect on HR- BP & myocardial oxygen consumption
Click here to read full press release/ article | Ref: PRNewswire | Image: PRNewswire
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com